Patients not at their LDL-C goal on maximum tolerated dose of LLT at baseline (n=127) | Baseline | 12 weeks | 95% CI | |
n (%) | n (%) | Mean LDL-C change ±SD (mg/dL) | ||
n=127 | n=127 | n=91 | ||
Alirocumab monotherapy | 26 (20.5) | 23 (18.1) | −48.0±14.1 | −57.5 to −37.7 |
Alirocumab + statin | 60 (47.2) | 51 (40.2) | −50.0±23.2 | −67.9 to −35.0 |
Alirocumab + other LLT | 21 (16.5) | 21 (16.5) | −56.3±11.4 | −62.7 to −45.5 |
Alirocumab + statin + other LLT | 20 (15.7) | 32 (25.2) | −53.8±17.5 | −62.7 to −40.3 |
Patients with statin intolerance or contraindication at baseline (n=128) | n=128 | n=128 | n=64 | |
Alirocumab monotherapy | 37 (28.9) | 32 (25.0) | −48.2±13.4 | −57.4 to −40.4 |
Alirocumab + statin | 52 (40.6) | 45 (35.2) | −43.2±22.4 | −58.9 to −28.5 |
Alirocumab + other LLT | 29 (22.7) | 30 (23.4) | −56.3±11.4 | −62.7 to −45.5 |
Alirocumab + statin + other LLT | 10 (7.8) | 21 (16.4) | −45.0±10.2 | −51.6 to −39.4 |
Patients not at goal or with statin intolerance/contraindication at baseline (n=175) | n=175 | n=175 | n=94 | |
Alirocumab monotherapy | 41 (23.4) | 36 (20.6) | −48.3±13.3 | −57.4 to −40.4 |
Alirocumab + statin | 82 (46.9) | 71 (40.6) | −50.3±23.0 | −66.9 to −36.2 |
Alirocumab + other LLT | 29 (16.6) | 30 (17.1) | −56.3±11.4 | −62.7 to −45.5 |
Alirocumab + statin + other LLT | 23 (13.1) | 38 (21.7) | −53.8±17.5 | −62.7 to −40.3 |
LDL-C, low density lipoprotein cholesterol; LLT, lipid-lowering therapy.